Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bala Cynwyd, PA, US. The stock last traded at $4.31, up 7.48% on the session, giving a market capitalisation of $447.7M. On trailing twelve-month figures it carries a trailing P/E of -2.17, a net margin of 0.0%. Its beta of 0.75 implies it has historically moved less than the broad market.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Larimar Therapeutics, Inc. is most often compared with the following Healthcare names: